
March 1 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:
RHYTHM PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE DATA FROM PHASE 3 TRANSCEND TRIAL OF SETMELANOTIDE IN PATIENTS WITH ACQUIRED HYPOTHALAMIC OBESITY
RHYTHM PHARMACEUTICALS INC - PDUFA GOAL DATE FOR SETMELANOTIDE IS MARCH 20, 2026
RHYTHM PHARMACEUTICALS INC - PRIMARY ENDPOINT ACHIEVED WITH 16.4% BMI REDUCTION